Cargando…

SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins

INTRODUCTION: Since 2008 United State (US) food drug administration mandate, several newer anti-diabetic drugs (ADD) have undergone a mandatory cardiovascular (CV) outcome trial (CVOT) in type diabetes (T2DM) patients with high CV risk. These includes CVOT done with dipeptidyl-peptidase-4 inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Awadhesh K., Singh, Ritu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540886/ https://www.ncbi.nlm.nih.gov/pubmed/31161099 http://dx.doi.org/10.4103/ijem.IJEM_12_19

Ejemplares similares

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial)
por: Aoki, Yasunori, et al.
Publicado: (2021)

Dynamic TIMI Risk Score for STEMI
por: Amin, Sameer T., et al.
Publicado: (2013)

Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: A nationwide observational study
por: Norhammar, Anna, et al.
Publicado: (2019)

Importance of the TIMI frame count: implications for future trials
por: Appleby, Mark A, et al.
Publicado: (2000)

The TIMI Study Group’s Contributions to the Advancement of Cardiology -With Focus on Atherosclerotic Cardiovascular Disease-
por: Toda Kato, Eri, et al.
Publicado: (2021)

TIMI perfusion grade compared to TIMI flow in prediction of infarct size and microvascular obstruction measured by contrast-enhanced MRI
por: Fuernau, Georg FK, et al.
Publicado: (2009)

Implications of the PEGASUS-TIMI 54 trial for US clinical practice
por: Bradley, Steven M, et al.
Publicado: (2017)

Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS‐TIMI 54 Trial
por: Furtado, Remo H. M., et al.
Publicado: (2020)

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial
por: Mosenzon, Ofri, et al.
Publicado: (2022)

Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study
por: Escobar, Carlos, et al.
Publicado: (2022)

Comparison of Prediction Between TIMI (Thrombolysis in Myocardial Infarction) Risk Score and Modified TIMI Risk Score in Discharged Patients From Emergency Department With Atypical Chest Pain
por: Abbasnezhad, Mohsen, et al.
Publicado: (2014)

The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial
por: McEwan, Phil, et al.
Publicado: (2021)

Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial
por: Bergmark, Brian A., et al.
Publicado: (2021)

Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial
por: Wilkinson, Chris, et al.
Publicado: (2020)

Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease
por: Bergmark, Brian A., et al.
Publicado: (2018)

Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54
por: Bonaca, Marc P., et al.
Publicado: (2018)

Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial
por: Kato, Eri Toda, et al.
Publicado: (2016)

An Asian Validation of the TIMI Risk Score for ST-Segment Elevation Myocardial Infarction
por: Selvarajah, Sharmini, et al.
Publicado: (2012)

Discrepancy Between Clinician and Research Assistant in TIMI Score Calculation (TRIAGED CPU)
por: Taylor, Brian T., et al.
Publicado: (2015)

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial
por: Murphy, Sabina A., et al.
Publicado: (2008)

Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function
por: Salvatore, Teresa, et al.
Publicado: (2021)

Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes
por: Husted, Steen, et al.
Publicado: (2016)

Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF‐TIMI 48 Trial
por: Eisen, Alon, et al.
Publicado: (2016)

TIMI 3 flow after primary angioplasty is an important predictor for outcome in patients with acute myocardial infarction
por: Kammler, Juergen, et al.
Publicado: (2008)

Screening Characteristics of TIMI Score in Predicting Acute Coronary Syndrome Outcome; a Diagnostic Accuracy Study
por: Alavi-Moghaddam, Mostafa, et al.
Publicado: (2017)

Unstable angina and non-ST-segment elevation myocardial infarction: an analysis by TIMI score
por: Arruda, SLM, et al.
Publicado: (2007)

Unstable angina and non-ST-segment elevation myocardial infarction: an analysis by TIMI score
por: Arruda, SLM, et al.
Publicado: (2009)

Evaluate the Correlation between the TIMI Frame Count, IMR, and CFR in Coronary Microvascular Disease
por: Xu, Xinye, et al.
Publicado: (2022)

The “Dual-Pathway” Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2-TIMI 51 Trial
por: Cohen, Marc, et al.
Publicado: (2014)

Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Post‐Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACS‐TIMI 46 and ATLAS ACS 2‐TIMI 51
por: Gibson, William J., et al.
Publicado: (2019)

GRACE Score among Six Risk Scoring Systems (CADILLAC, PAMI, TIMI, Dynamic TIMI, Zwolle) Demonstrated the Best Predictive Value for Prediction of Long-Term Mortality in Patients with ST-Elevation Myocardial Infarction
por: Littnerova, Simona, et al.
Publicado: (2015)

Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF‐TIMI 48 Trial
por: Eisen, Alon, et al.
Publicado: (2017)

Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 Trial
por: Fanola, Christina L., et al.
Publicado: (2018)

Can Timi Risk Score Predict Angiographic Involvement in Patients with St-Elevation Myocardial Infarction?
por: Golabchi, Allahyar, et al.
Publicado: (2010)

Prognostic Value of TIMI Score versus GRACE Score in ST-segment Elevation Myocardial Infarction
por: Correia, Luis C. L., et al.
Publicado: (2014)

Correlation of increased corrected TIMI frame counts and the topographical extent of isolated coronary artery ectasia
por: Wu, Wei, et al.
Publicado: (2018)

Association between High Lipid Burden of Target Lesion and Slow TIMI Flow in Coronary Interventions
por: Lim, Subin, et al.
Publicado: (2022)

Risk Stratification of Acute-Onset Chest Pain: SVEAT Score Versus HEART and TIMI Scores
por: Shahid, Muhammad F, et al.
Publicado: (2023)

HEART and TIMI Scores Predict Severe Coronary Atherosclerosis in Patients With End-Stage Renal Disease
por: Parikh, Trishna B, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vnos9r3gkl55ku6o5tuu12g2si